Kabipac Glucosa (Glucose Monohydrate)

Glucose monohydrate dissolves to release free glucose, which enters the bloodstream after IV infusion. Cells take up the glucose via GLUT transporters, using it in glycolysis and the citric acid cycle to generate ATP, the primary energy currency for cellular functions.

The dose of Kabipac Glucosa is determined by the prescribing clinician based on the patient’s clinical condition, blood glucose level, and overall fluid requirements. Dosage is individualized and should follow the prescriber’s order and institutional protocols.

Safety data for Kabipac Glucosa in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician.

To order Kabipac Glucosa, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Kabipac Glucosa is a sterile glucose monohydrate solution comparable to other IV glucose preparations in concentration and composition. Its distinguishing features are EU‑origin manufacturing, compliance with Good Distribution Practice, and availability through GNH India’s global supply network.

Store Kabipac Glucosa at ambient temperature, preferably below 25 °C. Keep the vial in its original packaging, protect it from direct light and moisture, and do not freeze. Inspect the solution for particulate matter before use.

Kabipac Glucosa is administered intravenously. It may be given as a direct infusion or diluted in compatible IV fluids according to the prescriber’s instructions, with infusion rates adjusted to avoid rapid changes in blood glucose.

Serious risks include severe hyperglycemia, hypersensitivity reactions such as anaphylaxis, and infection from contaminated solutions. Clinicians should monitor blood glucose closely, observe for signs of allergic response, and ensure aseptic handling during preparation and administration.

Kabipac Glucosa should be avoided in patients with known hypersensitivity to glucose monohydrate, those with uncontrolled severe hyperglycemia, or individuals for whom rapid glucose infusion is contraindicated, such as certain cases of diabetic ketoacidosis.